Clofarabine-based combination chemotherapy for relapse and refractory childhood acute lymphoblastic leukemia. 2014

Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
Department of Hematology/Oncology, Saitama Children's Medical Center.

Clofarabine, one of the key treatment agents for refractory and relapsed acute lymphoblastic leukemia (ALL), achieves a remission rate of approximately 30% with single-agent clofarabine induction chemotherapy. However, a remission rate of approximately 50% was reported with a combination chemotherapy regimen consisting of clofarabine, etoposide, and cyclophosphamide. We treated two cases with refractory and relapsed ALL with combination chemotherapy including clofarabine; one was an induction failure but the other achieved remission. Both cases developed an infectious complication (NCI-CTCAE grade 3) and body pain with infusion. Prophylactic antibiotic and opioid infusions facilitated avoiding septic shock and pain. Further investigation of such cases is required.

UI MeSH Term Description Entries
D008297 Male Males
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002437 Cefazolin A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. Cephazolin,Ancef,Cefamedin,Cefamezine,Cefazolin Sodium,Cephamezine,Cephazolin Sodium,Gramaxin,Kefzol,Sodium Cephazolin,Totacef,Cephazolin, Sodium,Sodium, Cefazolin,Sodium, Cephazolin
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005283 Fentanyl A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078) Phentanyl,Duragesic,Durogesic,Fentanest,Fentanyl Citrate,Fentora,R-4263,Sublimaze,Transmucosal Oral Fentanyl Citrate,R 4263,R4263
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
June 2012, American journal of hematology,
Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
March 1979, Cancer,
Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
January 1989, Cancer chemotherapy and pharmacology,
Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
August 1996, Blood,
Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
February 1984, Cancer treatment reports,
Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
May 2017, Pediatric hematology and oncology,
Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
December 2009, American journal of hematology,
Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
January 2020, Frontiers in oncology,
Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
March 1978, Blood,
Yuki Arakawa, and Katsuyoshi Koh, and Takahiro Aoki, and Yasuo Kubota, and Ryo Oyama, and Makiko Mori, and Mayumi Hayashi, and Ryoji Hanada
January 2020, Frontiers in oncology,
Copied contents to your clipboard!